Delequamine

Delequamine
Clinical data
Other names	DMMIN; RS-15385; RS 15385; RS15385; RS 15385-197; RS-15385-197; RS15385-197
Drug class	α2-Adrenergic receptor antagonist
Identifiers
	IUPAC name (8aR,12aS,13aS)-3-methoxy-12-methylsulfonyl-5,6,8,8a,9,10,11,12a,13,13a-decahydroisoquinolino[2,1-g][1,6]naphthyridine;
CAS Number	119813-87-5 ; 119905-05-4;
PubChem CID	60713;
ChemSpider	54718;
UNII	L37HF85G8S;
ChEMBL	ChEMBL163911;
CompTox Dashboard (EPA)	DTXSID301350815 ;
Chemical and physical data
Formula	C18H26N2O3S
Molar mass	350.48 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC2=C(C=C1)[C@@H]3C[C@H]4[C@H](CCCN4S(=O)(=O)C)CN3CC2;
	InChI InChI=1S/C18H26N2O3S/c1-23-15-5-6-16-13(10-15)7-9-19-12-14-4-3-8-20(24(2,21)22)17(14)11-18(16)19/h5-6,10,14,17-18H,3-4,7-9,11-12H2,1-2H3/t14-,17+,18+/m1/s1; Key:JKDBLHWERQWYKF-JLSDUUJJSA-N;

Delequamine (INNTooltip International Nonproprietary Name; developmental code names RS-15385, RS-15385-197) is a potent and selective α₂-adrenergic receptor antagonist which was under development for the treatment of erectile dysfunction and major depressive disorder but was never marketed.^[1]^[2]^[3]^[4]

It is structurally related to the naturally occurring α₂-adrenergic receptor antagonist yohimbine but has greater selectivity in comparison.^[3]^[4] The drug has been found to affect sexual function and sleep in humans.^[4]

Delequamine reached phase 3 clinical trials prior to the discontinuation of its development.^[1] The drug was under development in the 1990s and its development was discontinued by 1999.^[1] It was first described in the scientific literature by 1990.^[5]

References

^ ^a ^b ^c "Delequamine". AdisInsight. 22 September 1999. Retrieved 21 October 2024.
^ Ganellin, C.R.; Triggle, D.J. (1996). Dictionary of Pharmacological Agents. Taylor & Francis. ISBN 978-0-412-46630-4. Retrieved 21 October 2024.
^ ^a ^b Doherty, A.M.; Greenlee, W.; Hagmann, W.K.; Plattner, J.J.; Robertson, D.; Trainor, G.L.; Wong, W.W. (1999). Annual Reports in Medicinal Chemistry. Annual Reports in Medicinal Chemistry. Academic Press. p. 78. ISBN 978-0-08-058378-5. Retrieved 21 October 2024.
^ ^a ^b ^c Bancroft J (March 2000). "Effects of alpha-2 blockade on sexual response: experimental studies with Delequamine (RS15385)". Int J Impot Res. 12 (S1): S64 – S69. doi:10.1038/sj.ijir.3900507. PMID 10849567.
^ Clark, R. D., Spedding, M., & MacFarlane, C. B. (1990). RS-15385-197, a potent andselective alpha2-adrenoceptor antagonist. Br. J. Pharmacol, 99, 123P. https://scholar.google.com/scholar?cluster=6701996947549813409

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[AdisInsight-1] "Delequamine". AdisInsight. 22 September 1999. Retrieved 21 October 2024.

[GanellinTriggle1996-2] Ganellin, C.R.; Triggle, D.J. (1996). Dictionary of Pharmacological Agents. Taylor & Francis. ISBN 978-0-412-46630-4. Retrieved 21 October 2024.

[DohertyGreenleeHagmann1999-3] Doherty, A.M.; Greenlee, W.; Hagmann, W.K.; Plattner, J.J.; Robertson, D.; Trainor, G.L.; Wong, W.W. (1999). Annual Reports in Medicinal Chemistry. Annual Reports in Medicinal Chemistry. Academic Press. p. 78. ISBN 978-0-08-058378-5. Retrieved 21 October 2024.

[Bancroft2000-4] Bancroft J (March 2000). "Effects of alpha-2 blockade on sexual response: experimental studies with Delequamine (RS15385)". Int J Impot Res. 12 (S1): S64 – S69. doi:10.1038/sj.ijir.3900507. PMID 10849567.

[ClarkSpeddingMacFarlane1990-5] Clark, R. D., Spedding, M., & MacFarlane, C. B. (1990). RS-15385-197, a potent andselective alpha2-adrenoceptor antagonist. Br. J. Pharmacol, 99, 123P. https://scholar.google.com/scholar?cluster=6701996947549813409

[1]

[2]

[3]

[4]

[5]